ArticleInternational urogynecology journal2026
Intradetrusor OnabotulinumtoxinA Safety and Efficacy in Patients 80 Years and Older: A Retrospective Cohort Study.
Article in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine Learning Analysis of Risk Factors for Catheter-Associated Urinary Tract Infections in Stroke Patients and Their Impact on Healthcare Quality.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introduction and hypothesisOveractive bladder (OAB) has higher prevalence and increased morbidity in older people. Owing to side effects and inefficacy of OAB medications, patients frequently choose onabotulinumtoxin A intradetrusor injections (BTX-A). There is limited research investigating efficacy and adverse event (AE) rates of BTX-A in older female populations. Our objective was to evaluate rates of BTX-A discontinuation, treatment failure, UTI, and retention in women ≥ 80 compared to younger cohorts.
methodsThis retrospective cohort study included a convenience sample of women who underwent in-office BTX-A for OAB between 1/2014 and 12/2020. Data was analyzed with Kruskal-Wallis, ANOVA, chi-square, and Fisher's exact tests.
resultsOverall, 547 women were included with 215 (39%) < 65 years old, 249 (46%) 65-79, and 83 (15%) ≥ 80. When comparing age cohorts, rate of BTX-A discontinuation increased with age (54% at < 65, 58% 65-79, 72% ≥ 80, p = 0.01) with no significant difference in discontinuation due to ineffectiveness (19% < 65, 28% 65-79, 23% ≥ 80, p = 0.22). Those < 65 had the lowest rate of UTI (19%), but UTI rate was the same for women 65-79 (29%) and ≥ 80 (29%, p < 0.01). Rates of retention were highest in women 65-79 (8% < 65, 17% 65-79, 8% ≥ 80, p = 0.01).
conclusionsWomen ≥ 80 years old were most likely to discontinue BTX-A but discontinuing for ineffectiveness was the same regardless of age. Women > 65 are more likely to experience UTI after BTX-A; however, AEs do not significantly increase in women ≥ 80 years old, making BTX-A a good option in elderly patients.
Indexed as
Identifiers
41385082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.